Analyst at RBC Capital Markets
Appears in 1 story
Called the ALOFT-IPF efficacy 'encouraging, but confounding'
Bristol Myers Squibb's experimental lung disease drug admilparant met its main goal in a late-stage trial, but only at the lower of two tested doses. The 60 milligram dose significantly slowed the decline in lung function among patients with idiopathic pulmonary fibrosis, while the 120 milligram dose missed the statistical threshold.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
